Matches in UGent Biblio for { <https://biblio.ugent.be/publication/1003108#aggregation> ?p ?o. }
Showing items 1 to 39 of
39
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B412303.
- aggregation creator B412304.
- aggregation creator B412305.
- aggregation creator B412306.
- aggregation creator B412307.
- aggregation creator B412308.
- aggregation creator B412309.
- aggregation creator B412310.
- aggregation creator person.
- aggregation date "2009".
- aggregation format "application/pdf".
- aggregation hasFormat 1003108.bibtex.
- aggregation hasFormat 1003108.csv.
- aggregation hasFormat 1003108.dc.
- aggregation hasFormat 1003108.didl.
- aggregation hasFormat 1003108.doc.
- aggregation hasFormat 1003108.json.
- aggregation hasFormat 1003108.mets.
- aggregation hasFormat 1003108.mods.
- aggregation hasFormat 1003108.rdf.
- aggregation hasFormat 1003108.ris.
- aggregation hasFormat 1003108.txt.
- aggregation hasFormat 1003108.xls.
- aggregation hasFormat 1003108.yaml.
- aggregation isPartOf urn:issn:0001-5644.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Treatment of chronic hepatitis C in patients with human immunodeficiency virus (HIV) with weekly peginterferon alpha-2b plus ribavirin: a multi-centred Belgian study".
- aggregation abstract "Background and study aims : In Belgium, 10-15% of patients infected with the human immunodeficiency virus (HIV) are coinfected with hepatitis C virus (HCV). Because of increased incidence of antiretroviral drug-related hepatotoxicity and more rapid clinical evolution towards end-stage liver disease, treatment of chronic hepatitis C becomes a priority. We report the results or a multi-centred Belgian study evaluating efficacy and safety of peginterferon alpha-2b plus ribavirin in HIV-HCV co-infected patients without AIDS and without decompensated liver disease. Patients and methods : Forty-one patients, all genotypes, were screened to participate. Eventually 37 received treatment with peginterferon alpha-2b (1.5 mu g/kg/week) plus daily weight-based ribavirin for 52 weeks. About one third of the patients were genotypes 1, 2/3, and genotype 4, most of the latter being of Central African origin. About 56% of the patients had severe fibrosis (Metavir score >= F3). Results : Sustained viral response (SVR) at 24 weeks of follow-up was observed in 10/37 (27%) of patients. SVR was higher in genotype 2/3 compared to genotype 1/4 (46.7% versus 13.6%; p = 0.06) and in low (F0-F1) versus high (F2-F4) grade fibrosis (p = 0.06). Treatment was withdrawn for side effects in 11/37 patients (30%). One Child A cirrhosis patient at the start of therapy died 7 months after treatment withdrawal as a result of severe haemolytic anaemia. Conclusions : It can be concluded that weight-based peginterferon alpha-2b plus ribavirin can be successful in selected HIV-HCV co-infected patients. Caution should be applied in patients with advanced liver disease. (Acta gastroenterol. belg., 2009, 72, 389-393).".
- aggregation authorList BK730573.
- aggregation endPage "393".
- aggregation issue "4".
- aggregation startPage "389".
- aggregation volume "72".
- aggregation aggregates 1003134.
- aggregation isDescribedBy 1003108.
- aggregation similarTo LU-1003108.